oasis 4 trial semaglutide Efficacy, Safety and PK of Once‐Daily Oral 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach In the OASIS 4 phase

Weight-loss drugs may cause mild side effects in some people such as nausea, constipation, and diarrhea

Insulin requirements often decrease substantially after gastric bypass due to improved insulin sensitivity, necessitating careful dose adjustments to prevent hypoglycaemia

That excess insulin doesnt just affect blood sugar

Nakagawa H, Inazawa J, Inoue K, Misawa S, Kashima K, Adachi H, Nakazato H, Abe T: Assignment of the human renal dipeptidase gene (DPEP1) to band q24 of chromosome 16

davawensis , encoding the energy independent flavin transport-catalyzing protein, enhanced roseoflavin sensitivity and riboflavin export from their cytoplasm and increased riboflavin yield (Table 3